Adalimumab for the treatment of Crohn’s disease

Crohn’s disease is a chronic inflammatory intestinal disorder characterized by chronic, recurrent, often granulomatous inflammation affecting any part of the intestines, but most frequently involving the small bowel and colon. The development of novel biologic agents targeting tumor necrosis factor has revolutionized the treatment of patients with moderate-to-severe Crohn’s disease. Adalimumab, a fully human anti-tumor necrosis factor monoclonal...